|
|
|
 |
|
 |
Aerosolized AAT **
(Alpha-1 Antitrypsin) Collaboration partners
PARI, a Germany based world leader specializing in inhalation solutions
Indication
 |
Bronchiectasis |
Characteristics
Ready to use liquid for inhaled administration, 2% solution
Status
|
A Phase II Clinical Trial is underway |
Profile
The benefits of Kamada's high purity AAT for inhalation include:
|
Greater patient convenience |
|
Greater patient compliance |
|
Reduced treatment costs |
|
Larger treatment population |
|
Additional / new potential indications |
Kamada's Aerosolized AAT to treat Bronchiectasis was granted as an Orphan Drug by the FDA
According to Dr. Charles L. Daley, Chair of the Steering Committee for the COPD foundation's newly formed Bronchiectasis Registry and research consortium, "We see great potential in Kamada's aerosolized AAT product for treating the Bronchiectasis patient population, estimated at 100,000 in the US alone."
** Under development
|
|
|
|
|
More
|
